Skip to main content

Advertisement

Table 2 Summary of MS History (Full Analysis Set)

From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study

  n mean ± sd median min-max
Years since MS diagnosis 64 2.1 ± 4.00 0.2 0.04–14.3
Mean number of relapses within the last 24 months prior to Rebif® Rebismart™ initiation 62 1.5 ± 0.76 1.0 0–4
Mean number of relapses in which corticosteroids were usedwere used were used 62 0.9 ± 0.71 1.0 0–3
Mean number of relapses within the last 12 months prior to Rebif® Rebismart™ initiation 63 1.1 ± 0.47 1.0 0–2
Mean number of relapses in which corticosteroids were used 62 0.9 ± 0.57 1.0 0–2